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Abbreviations 
ACD: Acid-citrate-dextrose  
ACS: Acute coronary syndrome 
ADP: Adenosine diphosphate 
AMP: Adenosine monophosphate 
BMS: Bare metal stent 
BSA: Bovine serum albumin 
CAD: Coronary artery disease 
CD: Cluster of differentiation 
CPDA: Citrate-phosphate-dextrose-adenine 
CYP: Cytochrome 
DAG: Diacylglycerol 
DES: Drug eluting stent 
EDTA: Ethylenediaminetetraacetic acid 
ELISA: Enzyme-linked immunosorbent assay 
FACS: Fluorescence activated cell sorting 
Fc: Fragment crystallisable 
FITC: Fluorescein isothiocyanate 
GLUT: Glucose transporter 
GP: Glycoprotein 
HEPES: Hydroxyethyl-piperazineethanesulfonic acid 
HIF-1α: Hypoxia-inducible factor 1-alpha 
IP: Immunoprecipitation 
IP3: Inositol triphosphate 
JAM: Junctional adhesion molecules 
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LVEF: Left ventricular ejection fraction 
MFI: Mean fluorescence intensity 
mRNA: Messenger ribonucleic acid 
NO: Nitric oxide 
NSTEMI: Non-ST-segment elevation myocardial infarction 
PBS: Phosphate buffered saline 
PBSF: Pre-B-cell growth stimulating factor  
PCI: Percutaneous coronary intervention 
PCR: Polymerase chain reaction 
PE: Phycoerythrin 
PECAM: Platelet endothelial cell adhesion molecule 
PGI: Prostaglandin I 
PRP: Platelet rich plasma 
RMP: Renal multipotent progenitor cell 
RT: Room temperature 
SDF-1: Stromal cell-derived factor 1 
SDS-PAGE: Sodium-dodecyl sulfate polyacrylamide gel electrophoresis 
SEM: Standard error of mean 
SLAM: Signalling lymphocyte adhesion molecule 
STEMI: ST-segment elevation myocardial infarction 
TPO: Thrombopoietin 
TRAP: Thrombin receptor agonist peptide 
vWf: Von Willebrand factor 
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Introduction 
Coronary artery disease 
Coronary artery disease: From the past to the present 
“Remarks on Angina Pectoris” by John Warren, M.D., appeared in 1812 as the first 
article in the first issue of The New England Journal of Medicine and Surgery. Warren’s 
description of angina pectoris derived from the Latin term angina, “infection of the 
throat”; from the Greek ά́́́γχο′νη, “strangling”; and from the Latin pectus, “chest”.1 At 
this time pathogenesis of angina pectoris was not known. Heberden was the first to 
clinically describe “Angina” in 1772.2 However, it took almost a century until 
pathologists considered coronary arteries and their thrombotic occlusion as cause of 
angina pectoris.3 In 1879, the pathologist Hektoen concluded, that myocardial 
ischemia was caused by coronary artery thrombosis.4 In the early 20th century, Herrick 
suggested absolute bed rest as the treatment of choice for patients suffering from 
angina pectoris. Furthermore, clinicians began to use the electrocardiogram for 
diagnosis of myocardial infarction.5,6 The management of people suffering an acute 
myocardial infarction stayed pretty much the same until the middle of the 20th century.3 
However, during the economic rise of the United States of America it was noticed, that 
obviously healthy men were affected by consequences of an acute myocardial 
infarction (AMI), meaning death or disability. Thus, in 1948 the National Heart, Lung 
and Blood Institute (NHLBI) started the Framingham Heart Study. The purpose of this 
study was to investigate the development of myocardial disease by studying the 
lifestyles of inhabitants in the town Framingham in Massachusetts. “Factors of risk in 
development of coronary heart disease”; this was the title of the institutes’ first findings 
dealing with cardiovascular risk factors. The study demonstrated that elevated blood 
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pressure and serum cholesterol levels were risk factors for developing coronary artery 
disease (CAD) and in consequence myocardial infarction.7  
  
 
 
 
 
 
 
 
 
 
 
 
Figure modified after O’Donnell CJ et al. Cardiovascular risk factors. Insights form 
Framingham Heart Study. 2008.  
With the identification of coronary risk factors, the concept of prevention was 
introduced. Until the year 1961, patients with AMI were prescribed with bed rest. 
However, many of these patients died within their stay in hospital probably due to fatal 
arrhythmias. Approximately 30% of patients after AMI died in hospital. This risk was 
reduced by half by introduction of early chest pain units, back then known as coronary 
care units. Those units featured monitoring by electrocardiogram and external 
defibrillation.3 Early in the 20th century, the French physiologist Bernard started to do 
cardiac catheterization on animals.8 These experiments led to the first cardiac 
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catherization procedure in humans, performed by Forssman in 1929.9 He actually did 
the procedure on himself. This self-experiment in turn led to the exploration of cardiac 
hemodynamics by Cournand and Richards. These three men won the Nobel Prize in 
Physiology and Medicine in 1956. Cardiac catheterization was the initial step for the 
development of coronary arteriography in 1958.10 Those two procedures became gold 
standard for diagnosis of myocardial function (MI) and vessel anatomy and provided 
the fundament for coronary artery bypass surgery.3 The field of invasive cardiology 
soon emerged, built on the pioneering work of Dotter and Judkins, although Grüntzig 
is considered the father of percutaneous interventional cardiology.3,11 Initially, the 
technique of choice was balloon angioplasty, which was soon improved by implantation 
of bare metal- and drug eluting stents (BMS, DES). In the 1970s, “the” strategy for 
reopening a thrombotic occlusion of a coronary artery was the application of a 
fibrinolytic agent, such as Streptokinase. Fibrinolysis reduced mortality.12,13 The 
addition of acetyl salicylic acid (ASA) led to a further reduction in mortality as shown in 
the Second International Study of Infarct Survival (ISIS-2).14  
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Results from the ISIS-2 trial showing that administration of ASA and streptokinase led 
to a decreased incidence of vascular death in patients after AMI. Figure taken from the 
ISIS-2 Collaborative Group. 1988.  
Coronary angioplasty and stenting, together with newer, more potent platelet inhibitors 
(e.g. P2Y12- and glycoprotein IIb-IIIa platelet–receptor blockers), further reduced intra-
hospital mortality.3 In patients suffering from severe impairment of left ventricular 
ejection fraction (LVEF%) after MI, implantation of pace makers (especially with 
biventricular stimulation), defibrillators (to prevent fatal arrhythmia) and assist devices 
(as the ultimate ratio and bridging therapy to transplantation) have further improved 
prognosis.15,16,17 
 
Stable CAD 
Definition and pathophysiology 
Stable CAD is a clinical syndrome most commonly caused by myocardial ischemia and 
characterized by discomfort in the chest, jaw, shoulder, back, or arms. These 
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symptoms are typically provoked by exercise or emotional stress and are relieved by 
rest or nitroglycerin. Less typically, discomfort may occur in the epigastric area.18 
Although the most common causes of myocardial ischemia are atherosclerotic lesions 
in the coronary arteries, it also occurs in dilated- and hypertrophic cardiomyopathy, 
aortic stenosis etc.18 The cause of myocardial ischemia is an imbalance between 
myocardial oxygen supply and consumption. Oxygen saturation in peripheral blood 
and myocardial oxygen extraction are stable factors in this mechanism under most 
circumstances. However, the amount of blood and therefore oxygen delivered to the 
myocardium depends to a great extent on the diameter of the lumen of the coronary 
arteries. The diameter decreases with progression of atherosclerotic lesions in the 
coronary vessel and in consequence may be completely occluded. These alterations 
decrease- or in the worst case cut off the oxygen supply to certain areas of the 
myocardium, leading to symptoms of angina pectoris and a minor- to severe 
impairment of myocardial function. Exercise or emotional stress cause the heart to 
consume more oxygen. This results in increased heart rate, myocardial contractility- 
and wall stress. Ischemia-induced sympathetic activation can further increase the 
severity of ischemia through a variety of mechanisms including a further increase of 
myocardial oxygen consumption and coronary vasoconstriction, a vicious circle.18 
Angina pectoris is probably caused by adenosine, which is released by the ischemic 
myocardial tissue and stimulates A1 receptors on cardiac nerve endings.19 Ischemia 
is followed by reversible contractile dysfunction known as “stunning”. Intermittent 
condition of ischemia may lead to chronic- but still reversible dysfunction of the 
myocardium called “hibernation”. A brief episode of ischemia may also lead to 
“preconditioning” of the myocardium. This causes an enhanced resistance to further 
ischemic conditions.18 In physiological conditions, coronary arteries may lower 
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vascular resistance to a great amount, leading up to a 6-fold increased perfusion under 
maximum exercise. Reduction in the luminal diameter by atherosclerotic plaques 
reduces the normal ability of the coronary vascular bed to reduce its resistance during 
maximal exercise with the consequence of ischemia dependent on the degree of 
obstruction and myocardial oxygen demands. When luminal obstruction is 40%, the 
maximal flow during exercise can usually be maintained. But luminal diameter 
reduction of 50% may be associated with ischemia when coronary blood flow becomes 
inadequate to meet cardiac metabolic demand during exercise or stress.20,21 
 
Acute coronary syndrome (ACS) 
Definition and pathophysiology 
ACS represents a life-threatening manifestation of atherosclerosis.  It is usually caused 
by acute thrombosis induced by a ruptured or eroded atherosclerotic coronary plaque, 
with or without concomitant vasoconstriction, causing a sudden and critical reduction 
in blood flow.22 Arteritis, trauma, dissection, thromboembolism, congenital anomalies, 
cocaine abuse, or complications of cardiac catheterization are rare causes of ACS.  
The cardinal clinical symptom leading to diagnosis is angina pectoris. 
Electrocardiography is used to classify patients in two different subgroups. 
Non-ST-Elevation-ACS:  
Patients with acute angina pectoris but without persistent ST-segment elevation 
in the electrocardiogram; These patients have persistent- or transient ST-
segment depression or T-wave inversion, flat T waves, pseudo-normalization of 
T waves, or no ECG changes at presentation. Depending on cardiac-troponin 
(cTn) (a marker for cardiac necrosis) the diagnosis is further specified in Non-
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ST-Elevation-Myocardial-Infarction (NSTEMI), if troponin values are elevated, 
or unstable angina, if troponin values present in normal range.22 An increased 
cTn concentration is defined as a value exceeding the 99th percentile of a 
normal reference population.23,24  
 ST-Elevation-Myocardial-Infarction (STEMI):  
Patients with acute angina pectoris and persistent (>20 min) ST-segment 
elevation; This condition usually reflects a total occlusion of a coronary artery. 
The therapeutic objective is to achieve rapid, complete, and sustained 
reperfusion by primary angioplasty or fibrinolytic therapy.22 
 
Platelets 
Discovery of platelets, their properties and therapies 
The first to report about platelets was Bizzozero, a pioneer in platelet research. He 
discovered platelets using intravascular microscopy and in vitro flow chamber 
experiments in 1881-1882.25,26 Bizzozero was the first one to correctly identify the role 
of platelets in hemostasis and thrombosis and to describe bone marrow 
megakaryocytes.27 Wright identified the megakaryocyte as the precursor cell of the 
platelet.28,29,30 In 1886, Osler established that platelets contribute to human thrombotic 
disorders by discovering them in atherosclerotic aortic lesions and on diseased heart 
valves.31 Many important clinical disorders were described in the late 19th and the early 
20th century, including immune thrombocytopenia, May–Hegglin anomaly, 
thrombocytopenic haemorrhage, Glanzmann thrombasthenia, thrombotic 
thrombocytopenic purpura, von Willebrand disease and Bernard–Soulier syndrome.25 
Histologic examination of sites of vascular injury in animals by light microscopy and 
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later electron microscopy led to discovery of platelet adhesion and aggregation, 
followed by degranulation, the loss of distinct borders between platelets, and platelet 
thrombus contraction.32,33 By investigation of serum it was found that thrombin is a 
strong platelet activator and that platelets are secretory cells that store and release the 
vasoactive serotonin.25,34 Observation of platelet adhesion to connective tissue further 
led to the finding that collagen is a potent platelet activator.31,35 Extensive studies of 
clot retraction established that platelets contain actin and myosin. Platelets were the 
first non-muscle cells discovered to possess these functions.36,37 Several therapies 
were invented in the early 20th century like platelet transfusion in cases of severe 
thrombocytopenia in 1910.38 It took nearly 35 years before platelet transfusion 
therapies were improved significantly, encouraged by increased mortality due to 
bleeding caused by radiation of nuclear weapons.39,40 Bleeding death caused by 
radiation therapy and the implementation of new chemotherapeutics led to further 
improvement of transfusion therapy. Therefore, platelet transfusion became crucial for 
success of chemotherapy.25,41 Splenectomy was introduced in 1916 based on the 
recommendation of Kaznelson, who was a medical student in Prague.42,43 
Furthermore, corticosteroid therapy for immune thrombocytopenia was invented in the 
middle of the 20th century.44 In 1994, purification and cloning of thrombopoietin (TPO) 
was established by several groups using the murine myeloproliferative leukaemia 
virus.45 TPO increases platelet count in animals and humans by enhancing both 
megakaryocyte proliferation and survival.25 The endothelial lining of blood vessels 
prevents platelet interactions with the vessel wall by both synthesizing platelet 
inhibitors and masking subendothelial platelet-adhesive proteins. In 1976 and 1977 
Moncader and Weksler demonstrated that endothelial cells secrete prostaglandin I2 
(prostacyclin).46,47 Subsequently endothelial cells were found to release the platelet 
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inhibitor nitric oxide (NO), which acts synergistically with prostacyclin.48,49,50 Finally, an 
endothelial ADPase was discovered by Marcus et al. which is capable of rapidly 
metabolising the platelet activator ADP to its inactive form AMP.51,52 Platelet receptors 
were initially characterized on biochemical responses and later on their ability to 
release intracellular Ca++.53,54 Understanding of platelet receptors was significantly 
improved by invention of the sodium-dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), which paved the way for detailed biochemical 
assessment and therefore was a great help in receptor characterization- and 
purification.55,56 The development of fluorescence-activated cell sorting (FACS) 
allowed analysis of the binding of antibodies to individual platelets and even to small 
platelet microparticles, which are biologically active and support blood 
coagulation.57,58,59,60,61 In the late 20th century diagnosis of disorders due to platelet 
receptors was revolutionized by introduction of the polymerase chain reaction (PCR) 
which allowed studying of small mRNA.62 In arterial thrombosis, the role of platelets for 
a long time was subject of speculation. This changed in 1967 by pioneering work of 
Mustard et al. who demonstrated ischemia and arrhythmias in pig hearts after injection 
of ADP.63,64 The antithrombotic effects of ASA in many animal- and experimental 
models led to a systematic assessment of antithrombotic effects of ASA in humans.62,65 
In 1974, it was reported that thienopyridine and furopyridine had anti-inflammatory 
effects and inhibited platelet aggregation after administration of ADP in rats.66 The 2-
chloro thienopyridine derivative, later named ticlopidine, was found to be a potent 
prodrug inhibitor of platelet aggregation. It selectively inhibits ADP-induced platelet 
aggregation and prevents fibrinogen binding to αIIbβ3.25 Ticlopidine was found to be 
superior to aspirin especially in secondary prevention of vascular events.25 Most 
importantly however, it was shown that the combination of ASA and ticlopidine 
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prevented from instent thrombosis after coronary stenting.67 On the other hand, 
ticlopidine was demonstrated to have severe side effects like significant neutropenia 
in about 1% of patients.68 In 1998, clopidogrel, another thienopyridine was approved 
for clinical use. The efficacy in secondary prevention and prevention of instent 
thrombosis in combination with ASA was similar to ticlopidine while clopidogrel having 
a significantly better toxicity profile.69,70,71 Prasugrel was the third thienopyridine 
approved for clinical use. It achieves greater platelet inhibition than clopidogrel and it 
is unaffected by the CYP2C19 variants that seriously impair the effect of clopidogrel. 
In clinical studies prasugrel demonstrated both increased antithrombotic efficacy and 
increased risk of bleeding compared to clopidogrel, with the elderly and those with low 
body weight or a history of previous stroke or transient ischaemic attack at greatest 
risk of bleeding. Therefore, prasugrel is nowadays reserved for patients with acute 
coronary syndromes and tolerable bleeding risk.72 Ticagrelor, a non-thienopyridine 
P2Y12 inhibitor, is in clinical use in the European Union since 2010 and in the United 
States of America since 2011, respectively. Ticagrelor is an oral-acting, direct inhibitor 
that has rapid onset- and offset of action.25 It demonstrated antiplatelet effects in 
patients who did not respond to clopidogrel and greater overall antithrombotic efficacy 
than clopidogrel in a pivotal study.73,74 αIIbβIII (GP IIb/IIIa) antagonists like abciximab, 
eptifibatide and tirofiban are antithrombotic drugs that exert their platelet inhibitory 
effects by ligand binding to GP IIb/IIIa.25 These drugs, that have to be administered 
intravenously, show potent antithrombotic effects but on the other hand may cause 
severe bleeding complications.25 They demonstrated efficacy in reducing ischaemic 
complications of PCI and the treatment of ACS.75,76,77 However, due to the high risk of 
haemorrhage GP IIb/IIIa antagonists are reserved for patients with the highest risk of 
thrombosis.25 
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Figure modified after Hämostaseologie für die Praxis: Sicher durch den klinischen 
Alltag. 2010 
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Morphology, secretion, adhesion and aggregation 
Platelets are the smallest cells in peripheral blood with a diameter of 2.0 to 5.0 μm, a 
thickness of 0.5 μm and a volume of 6-10 femtoliters.78,79,80,81 Platelets have a life span 
of 7-10 days and get then removed from peripheral circulation by the 
reticuloendothelial system if not previously involved in hemostasis or thrombosis.82 
Platelets derive from their progenitors, the megakaryocytes. Megakaryocytes derive 
from pluripotent stem cells and undergo multiple DNA replications without cell divisions 
by the unique process of endo-mitosis.83 Platelets are rich in secretory granules which 
are essential for platelet function. 3 types of granules can be differentiated: α–granules, 
dense granules, and lysosomes with α-granules being the most abundant.84 The 
content of α–granules includes both membrane bound proteins that become expressed 
on the platelet surface and soluble proteins that are released into the extracellular 
space.85 These proteins include integrins (e.g. αIIb, α6, β3), immunoglobulin family 
receptors (e.g. GPVI, Fc receptors, PECAM), leucine-rich repeat family receptors (e.g. 
GPIb-IX-V complex), tetraspanins (e.g. CD9) and other receptors (e.g. CD36, Glut-
3).86,87,88,89,90 Platelets secrete many mediators involved in blood coagulation. Platelet 
dense granules contain high concentrations of low molecular weight compounds that 
potentiate platelet activation (e.g. ADP, serotonin, and calcium). However, α-granules 
contain large polypeptides like fibrinogen and von Willebrand factor (vWf), that 
contribute both to primary- and secondary hemostasis.82 Adhesive receptors like GPIb-
IX-V, the major receptor for fibrinogen, integrin αIIbβ3, and the collagen receptor GPVI 
are found in α-granules and also participate in platelet adhesion.83,88 Under physiologic 
conditions, platelets circulate preferentially in close proximity to vascular walls without 
interacting with endothelial cells. This behavior provides a natural resistance to 
thrombosis.91,92 When the continuity of endothelial layer is disrupted and the underlying 
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subendothelial matrix is exposed, a coordinated series of events are set in motion to 
seal the defect. Platelets play the primary role in this process.93 A key initial step in 
platelet adhesion to the site of injury involves interactions between the GP Ib-IX-V 
complex and the A1 domain of vWf in the exposed subendothelium.94,95,96 Endothelial 
cells serve as a barrier between circulating platelets and different types of collagen 
localized in the subendothelial matrix.97 The platelet receptors GPVI and α2β1 mediate 
the interaction between platelets and collagen. However, these interactions require 
previous platelet capture through the vWf/GP Ib complex. Both GPVI and α2β1 
mediate collagen-induced platelet activation under flow conditions, though the precise 
sequence of these interactions is not entirely clear yet.91 However, a variety of 
inflammatory states may result in platelet adhesion to endothelial cells in the absence 
of denudation and without evidence of significant alterations in the endothelial integrity. 
These processes may result from inhibition of the endogenous mechanisms preventing 
platelet adhesion (e.g. nitric oxide, prostacyclin, ADPase) and/or by inducing 
endothelial release of molecules that promote platelet adhesion. After initial adhesion 
of platelets to the site of the injury, platelet aggregation is needed for effective 
hemostasis. Following adhesion, platelets are activated by a number of agonists such 
as ADP and collagen that are present at the sites of vascular injury. These agonists 
activate platelets by binding to specific receptors on the platelet surface discussed 
earlier. Occupancy of these receptors leads to a series of downstream events that 
ultimately increases the intracytoplasmatic concentration of calcium ions.91 Calcium in- 
and efflux are mediated by diacylglycerol (DAG) and inositol triphosphate (IP3), 
respectively. Concentrations of DAG and IP3 are modulated by a series of G-protein 
coupled receptors as well as non-receptor tyrosin kinase pathways.94,98,99 Increased 
concentrations of free calcium in platelets lead to functional- and structural changes in 
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platelets. Morphologically, the platelet changes dramatically from a disc to a spiny 
sphere. This process is called “shape change”.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Electron microscopy of the shape change: (A) resting platelets; (B) activated platelets 
Figure taken from StudyBlue, Lincoln Memorial University. 
 
A 
B 
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The “release action” means that the granules in the platelet are centralized and their 
contents are discharged into the lumen of the open canalicular system, from which 
they are then released to the exterior.91 The “shape change” allows the platelets to 
form aggregates among each other.91 A main adhesion molecule involved in platelet 
aggregation is the GP IIb/IIIa complex. GP IIb/IIIa is an integrin receptor present at 
high density both on the plasma membrane and on α-granules of platelets.100 This 
complex is inactive in resting platelets and starts binding soluble plasma fibrinogen 
after conformational changes, induced by nearly every platelet activator. In turn, ligand 
binding of GP IIb/IIIa results in conformational changes directed to the cytoplasm.101,102 
Fibrinogen acts as a bridge between two GP IIb/IIIa molecules on adjacent platelets.94 
However, instead of fibrinogen, vWf acts as a bridge molecule between GP IIb/IIIa for 
platelet aggregation in conditions with high shear conditions, although platelet 
aggregation under lower shear is mediated by fibrinogen binding to GP IIb/IIIa.103 
Recently, several other molecules have been proposed to mediate platelet aggregation 
including junctional adhesion molecules (JAMs), signalling lymphocyte adhesion 
molecules (SLAMs) and CD40 ligand. The relative roles of these mechanisms in 
platelet aggregation have yet to be clearly defined.104,105,106 
Development of arterial thrombosis 
Consequences of arterial thrombosis such as myocardial infarction are one of the 
leading causes for death and disability in industrial countries. Usually, an arterial 
thrombus generates over an underlying atherosclerotic plaque in the high flow- and 
high shear conditions in the arterial circulation.107 In general, the thrombus forms over 
a ruptured plaque or an intact plaque with superficial endothelial erosion.91 In recent 
years, the understanding of plaque rupture and subsequent arterial thrombosis has 
changed. The occurrence of these events is probably affected to a greater extent by 
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plaque composition than plaque size and degree of stenosis.108 After plaque rupture, 
exposition of blood to the released procoagulant materials promotes thrombosis.91 
Under arterial shear stresses, only platelets are capable of adhesion to the damaged 
vessel wall. Several adhesion molecules and platelet activators are present in the 
plaque (e.g. collagen and oxidized lipids).109 However, unlike in venous thrombosis, 
coagulation factors do not seem to play a major role in arterial thrombosis since they 
are probably removed due to elevated flow in the arterial system. Atherosclerosis, 
hypertension, vascular anomalies etc. are considered to be risk factors for arterial 
thrombosis since these conditions lead to turbulence and altered flow in circulation and 
therefore facilitate platelet adhesion. Consequently, platelet hyperactivity plays an 
important role in the pathogenesis of arterial thrombosis.91 
 
Arterial thrombosis involves the formation of platelet-rich “white clots” that form after 
rupture of atherosclerotic plaques and exposure of procoagulant material such as lipid-
rich macrophages (foam cells), collagen, tissue factor, and/or endothelial breach, in a 
high shear environment. TM = thrombomodulin; II = prothrombin; IIa = thrombin; Fgn 
= fibrinogen; TF = tissue factor. 
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Figure and text taken from Wolberg AS, et al. Influence of cellular and plasma 
procoagulant activity on the fibrin network. 2010. 
 
The CXCR4/CXCR7-SDF-1 axis 
Chemokines and chemokine receptors 
Chemokines are a superfamily of chemoattracting, cytokine-like proteins that bind to- 
and activate a family of chemokine receptors. Over 50 chemokines have been 
identified, and they are divided into 4 families (CXC, CX3C, CC, and C) on the basis 
of the positions of 4 conserved cysteine residues.110 Chemokine receptors are seven-
transmembrane receptors coupled to G-proteins, all with their N-terminus outside the 
cell surface, three extracellular and three intracellular loops as well as a C-terminus in 
the cytoplasm. One of the intracellular loops of the chemokine receptors couples with 
heterotrimeric G-proteins. A ligand binds to the receptor which initiates a cascade of 
signal transduction events.111 Most chemokine receptors can bind various ligands. 
However, some chemokines bind to multiple receptors and some receptors in turn bind 
multiple chemokines, whereas certain chemokines interact with single receptors and 
some receptors bind only one chemokine.112 To date, at least 20 chemokine receptors 
have been identified. Chemokines and their receptors play important roles in 
inflammation, infection, tissue injury, allergy, cardiovascular diseases, and malignant 
tumors.113 
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SDF-1 (CXCL12) 
SDF-1 is a CXC chemokine. It was first cloned from a bone-marrow derived stromal 
stem cell and later recognized as a pre-B-cell growth stimulating factor (PBSF).110 
SDF-1 is expressed in a variety of tissues where it acts as a potent chemoattractant 
for hematopoetic cells.114,115 SDF-1 plays an important role in the homing of 
hematopoetic stem cells to the bone marrow and controlling human- and murine 
progenitor cell proliferation- and survival.116,117,118 SDF-1 in- and/or around injured 
tissues might create a stem cell-attracting environment which possibly results in 
organ- and tissue repair.119 SDF-1 is expressed substantially in cases where platelets 
adhere. Thereafter it causes recruitment of CD34+ cells and affects their proliferation 
and differentiation to various cell types like macrophages and foam cells or 
endothelial cells. 
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Figure modified after Stellos K, et al. Platelet Aggregates-Induced Human CD34+ 
Progenitor Cell Proliferation and Differentiation to Macrophages and Foam Cells Is 
Mediated by Stromal Cell Derived Factor 1 in Vitro. 2010. 
In bone marrow, SDF-1 is mainly produced by osteoblasts.120,121,122 SDF-1 regulates 
the migration of CD34+ cells. The chemoattractant activity of SDF-1 is significantly 
impaired when CXCR4 (a SDF-1 receptor) on CD34+ cells is neutralized or blocked.119 
SDF-1 expression is enhanced in endothelial cells expressing hypoxia-inducible factor 
1-alpha (HIF-1α).123 An elevated HIF-1α expression in hypoxic- or damaged tissues 
increases SDF-1 levels and therefore attraction of CXCR4+ stem cells leading to tissue 
regeneration.121 Several experimental studies have shown, that overexpression of 
SDF-1 in ischemic myocardium leads to in cardioprotection and improved myocardial 
function after myocardial infarction in vivo.124,125 It has been recently shown, that SDF-
1 is expressed on- and subsequently released by activated platelets.126 Plasma SDF-
1 is decreased in STEMI, compared to patients with stable CAD.127 
CXCR4 
CXCR4 is a highly conserved seven-transmembrane receptor that binds the ligand 
SDF-1.110 CXCR4 is expressed in a variety of tissues. In response to SDF-1, CXCR4 
can mediate leukocyte- and hematopoetic progenitor cell migration.128,129,130,131 It has 
been shown that the SDF-1/CXCR4 axis regulates the homing of human early 
hematopoietic cells in the bone marrow microenvironment. Mice with “knock-outs'' of 
CXCR4 genes usually die in utero and display severe hypocellularity of the bone 
marrow.127,132 Interestingly, the biological function of CXCR4 seems to change with 
maturation of cells. Human platelets for example become less responsive to SDF-1 
compared to their progenitors.133 
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CXCR7 
The existence of an exclusive receptor for SDF-1 has been questioned after the 
finding, that CXCR4 knock-out mice were still able to bind SDF-1.134 Additionally, 
discrepancies between CXCR4 expression and SDF-1 binding affinity in human cancer 
cell lines were shown.132 Thus, the presence of another SDF-1 binding receptor was 
suggested. This receptor was recently identified and named CXCR7.132,135 Like 
CXCR4, CXCR7 is a seven-transmembrane receptor.110 CXCR7 levels are elevated in 
endothelial cells of certain tumors. Furthermore, CXCR7 is expressed on activated 
endothelial cells, fetal liver cells, by the placenta and in the vascular 
endothelium.132,136,137,138,139 Neutralization of CXCR7 reduces the number of renal 
multipotent progenitor cells (RMP) in kidneys with acute renal failure. CXCR7 is 
required for transendothelial migration of RMPs and mediates their adhesion to 
endothelial cells. In addition CXCR7, but not CXCR4, is responsible for survival of 
RMPs.140 In a stroke model in rats, CXCR7 expression is up-regulated in tissue outside 
the primary ischemic lesion. SDF-1 might protect neurons and non-neuronal cells from 
ischemic damage via CXCR7.141 Further, there is some evidence that CXCR7 
exclusively mediates endothelial progenitor cell survival.142 However, the contribution 
of CXCR7 to SDF-1 mediated effects is to a large extent still unknown.  
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Aims  
There is emerging evidence that platelet surface expression of SDF-1 is enhanced 
during ischemic events and might play an important role in peripheral homing of stem 
cells and myocardial repair. Since SDF-1 effects are mediated through CXCR4/CXCR7 
we investigated platelet expression of SDF-1, CXCR4 and CXCR7 in patients with 
coronary artery disease (CAD). 
The aims of the thesis were the following: 
 To show expression of both CXCR4 and CXCR7 on platelets 
 To assess the surface expression of CXCR4 and CXCR7 on platelets of patients 
with either stable CAD or ACS 
 To assess a possible correlation between surface SDF-1 and both surface 
CXCR4 and CXCR7 on platelets 
 To investigate an influence of CXCR4 and CXCR7 expression on functional 
recovery in patients with ACS   
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Materials and methods 
Patient characteristics and blood sampling  
From March 2012 till May 2013 we performed a consecutive clinical study including 
patients suffering from symptomatic coronary artery disease (CAD) at the department 
of cardiology of the University of Tübingen. We were able to include 215 patients with 
CAD. 112 individuals presented with stable CAD whereas 103 suffered an acute 
coronary syndrome (ACS). Prior to percutaneous coronary intervention (PCI) 50ml of 
blood were drawn via the catheter sheet and analysed within one hour for platelet 
surface expression of CD42b, SDF-1, CXCR4 and CXCR7 by fluorescence-activated 
cell sorting (FACS). All subjects gave written informed consent. After initial submission 
of the manuscript underlying this doctor thesis we were asked to confirm  the findings 
in a healthy control group and therefore did a de-novo investigation of 5 healthy 
volunteers, 5 patients with stable CAD and another 5 individuals presenting with ACS. 
Definitions of stable CAD and ACS are provided in the introduction section of this 
thesis. The study was approved by the institutional ethics committee (270/2011BO1) 
and complies with the declaration of Helsinki and the good clinical practice 
guidelines.143,144,145 
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Table 1: Baseline patient characteristics in patients with acute coronary syndrome 
compared to patients with stable CAD 
Characteristics 
All 
(n=215) 
Acute 
Coronary 
Syndrome 
(n=103) 
Stable CAD 
(n=112) 
p 
n male 160 78 82 0.673 
n female 55 25 30 0.673 
Age years (Mean ± SD) 69 (± 11) 69 (± 11) 70 (± 12) 0.051 
CVRF 
 
Arterial Hypertension 
191 
(88.8%) 
84 (81.6%) 107 (95,5%) 0.006 
Hyperlipidaemia 
159 
(74.0%) 
67 (65.0%) 92 (82.1%) 0.332 
Diabetes 61 (28.3%) 29 (28.2%) 32 (28.6%) 0.866 
Smoking 40 (18.6%) 16 (15.5%) 24 (21.4%) 0.079 
Ex-Smoking (>6 months) 40 (18.6%) 19 (18.4%) 21 (18.8%) 0.931 
Atrial fibrillation 39 (18.1%) 18 (17.5%) 21 (18.8%) 0.615 
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LV function (EF%)  
(Mean ± SD) 
50.0  
(± 11.2) 
49.5 (± 10.2) 50.4 (± 12.0) 0.123 
LVEF% normal 79 (36.7%) 29 (28.2%) 50 (44.6%) 
0.042 
LVEF% mild impairment 44 (20.5%) 26 (25.2%) 18 (16.1%) 
LVEF% moderate 
impairment 
37 (17.2%) 22 (21.4) 15 (13.4%) 
LVEF% severe 
impairment 
32 (14.9%) 16 (15.5%) 16 (14.3%) 
LVEF% unknown 23 (10.7%) 10 (9.7%) 13 (11.6%) 
 
Renal function (GFR) 
(Mean ± SD) 
73.5  
(± 23.9) 
73.4 (± 26.8) 73.5 (± 21.2) 0.524 
Medication on admission 
 
Acetyl Salicylic Acid 
128 
(59.5%) 
56 (54.4%) 72 (64.3%) 0.362 
Clopidogrel 53 (24.7%) 14 (13.6%) 39 (34.8%) 0.001 
Prasugrel 6 (2.8%) 1 (1.0%) 5 (4.5%) 0.142 
Ticagrelor 12 (5.6%) 6 (5.8%) 6 (5.4%) 0.776 
Oral anticoagulants 26 (12.1%) 9 (8.7%) 17 (15.2%) 0.218 
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ACE inhibitors 
107 
(50.0%) 
43 (41.7%) 64 (57.1%) 0.066 
AT1-receptor antagonists 37 (17.2%) 14 (13.6%) 23 (20.5%) 0.265 
Beta blockers 
129 
(60.5%) 
48 (46.6%) 81 (72.3%) <0.001 
Statins 
128 
(59.5%) 
50 (48.5%) 78 (69.6%) 0.005 
 
 
Platelet surface expression measured by FACS 
Platelets in whole blood were analyzed for SDF-1, CXCR4, CXCR7 and the platelet 
specific marker CD42b. 50ml of blood were drawn through the catheter sheet into a 
common, sterile 50ml syringe. Immediately, we put this blood into tubes containing 
citrate-phosphate-dextrose solution with adenine (CPDA). Afterwards, CPDA blood 
was diluted 1:50 with phosphate buffered saline (PBS, Gibco) and incubated for 30 
minutes at room temperature with the following antibodies: CXCR4-PE, CXCR7-PE, 
SDF-1-CFS and CD42b-FITC (all mouse anti human, R&D, Beckman Coulter). For 
validation of our results we did respective isotype controls (R&D). After incubation the 
probes were fixed with 0.5% paraformaldehyde and thereafter analysed by FACS 
(Becton-Dickinson, Heidelberg, Germany). We further used the platelet activators 
thrombin receptor agonist peptide (TRAP) and ADP (Sigma-Aldrich) to analyze agonist 
induced changes in platelet surface expression of the markers of interest.  
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Immunofluorescence confocal microscopic analysis 
This analysis was initially not a part of our investigation. However, after initial 
submission to the European Heart Journal reviewers asked for another technique for 
validation of the FACS results. Therefore, we decided to perform immunofluorescence 
confocal microscopic analysis of CXCR4 and CXCR7 inside- and on the surface of 
platelets. We fixed platelets in platelet rich plasma (PRP) with 1% paraformaldehyde, 
applied them to 0.01% poly-L-lysine coated coverslips and then permeabilized 
platelets with 0.3% Triton X-100. We did not permeabilize platelets for surface 
expression analysis of the respective antibodies. After blocking with 1% bovine serum 
albumin-PBS for 1 hour at room temperature, samples were labelled overnight at 4°C 
with the following primary antibodies: mouse anti-human CXCR4 and rabbit anti-
human/mouse CXCR7 (R&D, Abcam). After washing, samples were incubated with 
corresponding secondary antibodies (Alexa Fluor 488 goat anti-rabbit IgG and Alexa 
Fluor 647 donkey anti-mouse IgG, Invitrogen) for 2 hours at room temperature. Finally, 
the coverslips were mounted with antifade fluorescence mounting medium. The 
images were taken with a confocal laser scanning microscope by Zeiss (Carl Zeiss 
Micro Imaging).  
Western Blot analysis  
Also this analysis was an answer to a reviewer’s question about the validity of the 
FACS results. We therefore performed western blot analysis to investigate SDF-1, 
CXCR4 and CXCR7 expression levels in a small subgroup consisting of 5 healthy 
volunteers, 5 patients with stable CAD and 5 ACS patients. First, we obtained PRP by 
centrifugation of blood in acid-citrate-dextrose (ACD) buffer at 200g for 20 minutes at 
room temperature. Afterwards, we washed the PRP in modified Tyrode-HEPES buffer. 
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After washing, we centrifuged the sample at 900g for another 10 minutes at room 
temperature. The resulting pellet was then resuspended in Tyrode-HEPES buffer. The 
carefully prepared platelets were lysed in immunoprecipitation (IP) buffer under resting 
conditions for 60 min at 4oC. Thereafter, western blot analysis was performed. Washed 
human platelets were lysed in immunoprecipitation (IP) buffer (15mM Tris-
hydrochloride, 155mM NaCl, 1mM EDTA, 0.08mM sodium azide, protease-
phosphatase inhibitor cocktail) for 60 min at 4oC. Samples were preheated for 10 min 
to 95°C after dilution with 2x Lämmli buffer + 5% mercaptoethanol. Processed samples 
were run on a 8.5% SDS-polyacrylamide gel electrophoresis (PAGE) gel for detection 
of CXCR4 (43KD), CXCR7 (50KD). Blotting onto a polyvinylidene difluoride membrane 
(Immibilon, Millipore) was performed using a SemiDry Transfer Cell System (Peqlab). 
Membranes were incubated overnight at 4°C with respective primary antibodies rabbit 
polyclonal anti-human CXCR4 (Abcam), rabbit polyclonal anti-human/mouse CXCR7 
(Abcam). For detection, corresponding secondary fluorochrome-labeled antibodies 
and the Odyssey infrared imaging system (LI-COR, Bad Homburg, Germany) were 
used. 
Enzyme-linked immunosorbent assay (ELISA) 
Besides measuring platelet surface expression of SDF-1 we investigated circulating 
SDF-1 levels by a commercially available ELISA kit (R&D) in a subgroup of 160 
patients. For storage, plasma probes were initially centrifuged for 15 min at 10 000 g 
within 30 minutes of collection. Samples were stored at -80°C until analysis.  
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Follow up of left ventricular function  
One main study objective was to investigate functional recovery after ACS. A 
parameter that can be measured quite easily and gives good information about the 
myocardial function is the left ventricular ejection fraction (LVEF%). For this part of the 
study we investigated just ACS patients since ACS often leads to an acute impairment 
of LVEF%. However, in an emergency situation like ACS, detailed echocardiography 
is sometimes not possible. Therefore, we decided to investigate LVEF% at baseline 
via ventriculography during PCI. Before hospital discharge we re-evaluated LVEF% by 
transthoracic echocardiography (TTE). After three months patients were re-scheduled 
for following up the course of LVEF% by TTE. LVEF% was assessed using the 
Simpson’s method.146 
Statistical analysis  
We analyzed all our data using SPSS version 21.0 (SPSS Inc., ChicagoIL). Normally 
distributed data like LVEF% were compared using repeated measures ANOVA. 
Results are demonstrated as mean values ± standard deviation (SD) in the form of bar 
diagrams. Non-parametric data, including MFIs were compared using the U-Test by 
Mann and Whitney. Results are shown as median values with 25th and 75th percentiles 
and in the form of box plots. Correlations were assessed using Spearman’s rank 
correlation coefficient (ρ) and are presented as scatter plots. Multivariate analysis 
was performed to show independent associations of CXCR4 and CXCR7 levels after 
normalization for CD42b receptor count.  
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Results 
Platelets express SDF-1 receptors CXCR4 and CXCR7 
The expression of both CXCR4 and CXCR7 on the surface of platelets is one of the 
major findings of our study. Western blot analysis shows that both CXCR4 and CXCR7 
are expressed in human platelets of healthy volunteers, patients with stable CAD and 
those with ACS (Figure 1A). As evidenced by immunofluorescence confocal 
microscopy (Figure 1B), we demonstrate that CXCR4 and CXCR7 are expressed both 
inside the platelet and on its surface. Intracellular analysis showed that CXCR4 was 
primarily localized towards platelet periphery on the plasma membrane under resting 
conditions, while CXCR7 was distributed both in the cytoplasm and plasma membrane 
(Figure 1B).  Figure 1C shows platelet surface expression (FACS) of SDF-1, CXCR4 
and CXCR7 in the three subgroups under resting condition and after activation with 
TRAP or ADP, respectively.147  
 
 
Figure 1A 
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Figure 1A taken from Rath D, et al. Expression of stromal cell-derived factor-1 
receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary 
syndrome and association with left ventricular functional recovery. European Heart 
Journal. 386-394. 2014. 
  
 
 
 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
Figure 1B 
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Figure 1B taken from Rath D, et al. Expression of stromal cell-derived factor-1 
receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary 
syndrome and association with left ventricular functional recovery. European Heart 
Journal. 386-394. 2014. 
 
 
 
 
 
 
 
 
 
 
Figure 1C 
Figure 1C taken from Rath D, et al. Expression of stromal cell-derived factor-1 
receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary 
syndrome and association with left ventricular functional recovery. European Heart 
Journal. 386-394. 2014.  
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Differential expression of CXCR4 and CXCR7 in patients with ACS 
compared to stable CAD 
Patients’ characteristics (age, gender, cardiovascular risk factors, co-medication) of 
the two subgroups stable CAD and ACS are provided in Table 1. CXCR4 expression 
was not elevated on the surface of platelets of ACS patients compared to the control 
group [median MFI 29.0 (25th; 75th percentile 23.5; 40.0) vs. 26.3 (25th; 75th 
percentile 20.3; 35.4), p=0.122]. In contrast, we could show significantly elevated 
platelet surface expression of CXCR7 in ACS patients as compared to patients with 
stable CAD [median MFI 17.8 (25th; 75th percentile 14.6; 27.3) vs. 15.3 (25th; 75th 
percentile 12.6; 20.6), p=0.004] (Figure 2 A and B).145 Since ACS consists of unstable 
angina pectoris, NSTEMI and STEMI we performed a more specific subgroup analysis. 
There were no statistically significant differences between these three subgroups. We 
could not find any significant difference CXCR4/-7 platelet surface expression with 
regard to antiplatelet pre-treatment. 
  
Figure 2A, 2B 
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Figure 2A and 2B taken from Rath D, et al. Expression of stromal cell-derived factor-
1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary 
syndrome and association with left ventricular functional recovery. European Heart 
Journal. 386-394. 2014. 
 
We found a moderate but significant correlation of CXCR4 and CXCR7 levels on 
platelet surface (ρ= 0.272, p< 0.001) and of platelet bound SDF-1 and CXCR4 (ρ= 
0.273, p< 0.001), respectively (Figure 3A and 3B). Additionally, there was a strong 
correlation of SDF-1 with CXCR7 expression levels (ρ= 0.454, p< 0.001) (Figure 
3C).145  
  
 
 
 
 
Figure 3A, 3B, 3C 
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Figure 3C taken from Rath D, et al. Expression of stromal cell-derived factor-1 
receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary 
syndrome and association with left ventricular functional recovery. European Heart 
Journal. 386-394. 2014. 
 
Next, we performed univariate analysis of covariance to investigate independent 
interrelations. We included several cardiovascular risk factors (e.g. hypertension and 
diabetes mellitus type II), cardiovascular comorbidities (e.g. atrial fibrillation), 
medication (e.g. ASA and ACE inhibitors) and platelet count in our model. No 
significant interrelations except for ACS vs. stable CAD on CXCR7 surface expression 
and beta blockers on CXCR4 surface expression could be shown (Table 2 and 3). 
Thus, we could demonstrate an independent association of platelet surface expression 
of CXCR7 but not CXCR4 with ACS. Furthermore, we measured circulating SDF-1 
levels in a subgroup of 160 patients. However, we could not show any significant 
correlations between circulating SDF-1- and platelet CXCR4 and CXCR7 levels.  
Table 2: Univariate analysis of covariance with CXCR4 levels as dependent variable 
and clinical factors as covariates 
Variable 
Point Estimates  
(lower bound – upper bound)  
95% Confidence Interval 
p 
CVRF  
Hypertension -0.16 (-8.81 – 8.50) 0.972 
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Hyperlipoproteinaemia -1.06 (-9.09 – 6.97) 0.795 
Smoker 1.32 (-5.04 – 7.66) 0.683 
Diabetes mellitus type II 0.77 (-4.28 – 5.82) 0.764 
Atrial fibrillation -2.52 (-8.97 – 3.93) 0.442 
Medication on admission  
Acetyl Salicylic Acid 3.97 (-1.47 – 9.41) 0.151 
Clopidogrel 4.39 (-1.05 – 9.83) 0.113 
Oral anticoagulants -0.33 (-7.67 – 7.01) 0.929 
ACE inhibitors -0.17 (-6.42 – 6.09) 0.958 
AT1-receptor antagonists 3.76 (-3.12 – 10.65) 0.282 
Beta blockers -5.35 (-10.24 – -0.46)  0.032 
Statins -3.09 (-11.07 – 4.88) 0.445 
Clinical factors 
 
Age 0.05 (-0.17 – 0.27) 0.651 
Gender 0.13 (-4.98 – 5.24) 0.960 
LVEF% 0.05 (-0.15 – 0.26) 0.600 
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GFR -0.03 (-0.14 – 0.08) 0.612 
Platelet count * 1000 0.00 (-0.03 – 0.04) 0.808 
Groups 
 
ACS vs stable CAD -0.87 (-5.43 – 3.68) 0.706 
 
 
Table 3: Univariate analysis of covariance with CXCR7 levels as dependent variable 
and clinical factors as covariates 
Variable 
Point Estimates  
(lower bound – upper bound)  
95% Confidence Interval 
p 
CVRF 
 
Hypertension 2.69 (-5.85 – 11.23) 0.534 
Hyperlipoproteinaemia -4.20 (-12.00 – 3.60) 0.289 
Smoker -1.50 (-7.67 – 4.67) 0.632 
Diabetes mellitus type II 1.80 (-3.19 – 6.79) 0.477 
Atrial fibrillation -2.39 (-8.67 – 3.89) 0.453 
Medication on admission 
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Acetyl Salicylic Acid -2.79 (-8.21 – 2.63) 0.311 
Clopidogrel 0.12 (-5.29 – 5.53)  0.965 
Oral anticoagulants 0.21 (-7.18 – 7.60) 0.955 
ACE inhibitors -1.29 (-7.55 – 4.96) 0.684 
AT1-receptor antagonists 2.36 (-4.54 – 9.27) 0.500 
Beta blockers -2.45 (-7.34 – 2.44) 0.325 
Statins 1.78 (-5.95 – 9.51) 0.694 
Clinical factors 
 
Age -0.152 (-0.370 – 0.66) 0.171 
Gender 2.89 (-2.24 – 8.02) 0.268 
LVEF% 0.01 (-0.19 – 0.21) 0.952 
GFR -0.04 (-0.14 – 0.06) 0.453 
Platelet count * 1000 -0.01 (-0.03 – 0.02) 0.716 
Groups 
 
ACS vs stable CAD 5.05 (0.58 – 9.52) 0.027 
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Follow-up of LVEF% 
One key finding of our study is, that high platelet CXCR7 is associated with LVEF% 
recovery after ACS. We found a significant association of CXCR7 but not CXCR4 
surface expression on absolute changes in LVEF% at 5 days and after 3 months of 
follow-up (46.2±10.7, 49.8±9.5, 53.7±9.1; p=0.003 for CXCR7> median vs. 52.1±9.5, 
51.5±9.0, 49.9±12.7; p=0.21 for CXCR7≤ median) (Figure 4). We could demonstrate 
an independent interrelation between CXCR7 expression levels on the platelet surface 
and LVEF% recovery (Table 4).145  
  
   
  
  
 
 
 
 
 
  
  
  
 
Figure 4 
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Figure 4 taken from Rath D, et al. Expression of stromal cell-derived factor-1 receptors 
CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome 
and association with left ventricular functional recovery. European Heart Journal. 386-
394. 2014. 
 
Table 4: Univariate analysis of covariance with LVEF% recovery as dependent variable 
and clinical factors as covariates 
Variable 
Point Estimates  
(lower bound – upper bound) 
95% Confidence Interval 
p 
Hypertension 1.07 (-35.79 – 37.94) 0.953 
Hyperlipoproteinaemia -0.7 (-19.11 – 17.71) 0.938 
Smoking 30.16 (4.68 – 55.64) 0.022 
Diabetes mellitus type II -7.73 (-30.10 – 14.63) 0.487 
Gender -6.65 (-29.15 – 15.84) 0.551 
Troponin I -0.06 (-0.23 – 0.10) 0.424 
CXCR7 >median 26.96 (8.92 – 45.01) 0.005 
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Discussion 
In our study we were able to show that (1) CXCR4 and CXCR7 are constitutively 
expressed inside- and on the surface of human platelets. (2) CXCR7- but not CXCR4 
surface expression is elevated in ACS patients as compared to patients with stable 
CAD. We found that (3) both CXCR4 and CXCR7 levels correlate with platelet bound 
SDF-1. Finally, we could demonstrate that (4) high CXCR7 levels are interrelated with 
LVEF% recovery after ACS.145  
Platelets are a major source for SDF-1.124 In the setting of ACS, platelet surface 
expression levels of SDF-1 are up-regulated. Platelet bound SDF-1 correlates with 
circulating SDF-1 levels.148 There is emerging evidence that SDF-1/CXCR4 
interactions are vital for the stem cells traffic to damaged tissue in vitro and in vivo. 
However, CXCR4 is not the exclusive receptor for SDF-1. Recently, CXCR7 has been 
identified as another specific receptor for SDF-1, mediating ligand internalization.136 
CXCR4 and CXCR7 interact with each other leading to changes in already existing 
CXCR4/G-protein complexes, thus impairing CXCR4-promoted calcium signalling and 
G-protein activation.149 Both expression and effects of CXCR4 and CXCR7 vary 
between different cell types. CXCR4 is crucial for SDF-1 mediated progenitor cell 
migration. On the other hand, CXCR7 seems to be important for progenitor cell 
adhesion and SDF-1 induced cell survival.138 Unaffected by its ligand SDF-1, CXCR7 
permanently cycles between intracellular compartments and plasma membrane. 
However, CXCR7 influences SDF-1 concentration and therefore gradients by its ability 
to scavenge and sequester SDF-1. Altered SDF-1 gradients might lead to diverse 
signalling by CXCR4.150,151 Incubation with SDF-1 affects CXCR4 and CXCR7 
differentially. While CXCR4 is down-regulated, internalized and degraded152, CXCR7 
experiences a dynamic internalization and time dependent externalization.153 There 
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are sparse data about these two SDF-1 receptors on platelets, especially in patients 
with coronary artery disease.  In our study we show for the first time that ACS goes 
hand in hand with elevated platelet surface expression of CXCR7. We could 
furthermore demonstrate that both CXCR4 and CXCR7 correlate with platelet surface 
expression of SDF-1. CXCR4 was elevated by trend, but not significantly in ACS 
patients compared to patients with stable CAD.145 Previous studies showed, that SDF-
1 incubation hardly affects CXCR7 expression.154 Thus, there is a possibility that 
hypoxia-induced enhanced platelet surface expression of CXCR7 prevails in the 
setting of ACS. Another important finding was the independent association of high 
CXCR7 levels and LVEF% recovery after ACS. In addition we found an independent 
association of CXCR7 expression on long-term improvement of LVEF%. We have 
already shown that platelet surface expression of SDF-1 is associated with LVEF% 
recovery in patients with acute myocardial infarction.155 CXCR7 might mediate these 
effects. When either CXCR4 or CXCR7 are neutralized, hypoxia preconditioned 
mesenchymal stem cells lose some of their therapeutic potential, pointing out the 
importance of CXCR4 and CXCR7 for repair mechanisms after ischemic events.152 
CXCR7 blockage can interfere with SDF-1/CXCR4 induced human endothelial 
progenitor cell (EPC) adhesion to active endothelium and trans-endothelial 
migration140. There exists evidence that the SDF-1/CXCR4/CXCR7 axis influences 
human progenitor cell survival after organ ischemia.132,138,140  In our present study we 
could not find significant confounding by hypercholesterolemia, platelet count or size 
and atrial fibrillation, which have been shown to possibly influence the SDF-
1/CXCR4/CXCR7 axis.156,157,158   
After investigation of circulating SDF-1 levels in 160 patients with symptomatic CAD, 
we could neither find a significant correlation with platelet surface expression of 
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CXCR4 nor CXCR7. This is surprising since there is a significant correlation of platelet 
surface SDF-1 with its receptors. However, our observation is in line with previous 
reports demonstrating that circulating SDF-1 levels do not necessarily correlate with 
CXCR4 expression.146  
In our present study we demonstrate a possible role of platelet CXCR7 on mediating 
beneficial SDF-1 driven effects on myocardial regeneration after ACS. Better 
understanding of the role of platelets and especially platelet derived CXCR4 and 
CXCR7 in stem cell function, recruitment and tissue regeneration will provide further 
insight into the myocardial recovery potential of these receptors. Further investigation 
of CXCR4 and CXCR7 might enable us to develop novel therapeutic strategies for 
patients with coronary artery disease.   
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Zusammenfassung 
In dieser Studie konnten wir zeigen, dass die SDF-1 Rezeptoren CXCR4 und CXCR7 
auf der Thrombozytenoberfläche exprimiert werden. Wenn wir die 
Oberflächenexpression von CXCR4 und CXCR7 in zwei Patientengruppen (stabile 
Angina Pectoris vs. akutes Koronarsyndrom) vergleichen, fällt auf, dass die CXCR7 
Expression bei Patienten mit akutem Koronarsyndrom deutlich erhöht ist. Dies gilt für 
CXCR4 nicht. In unserer Studie korrelierte thrombozytäres SDF-1 sowohl mit CXCR4 
als auch CXCR7. Abschließend konnten wir einen signifikanten Einfluss von CXCR7 
auf die Erholung der LV-Funktion nach ACS zeigen. 
Insgesamt wurden 215 Patienten in die Studie eingeschlossen (n=112 stabile Angina 
Pectoris, n=103 akutes Koronarsyndrom). Mittels Western Blot Analyse, 
Konfokalmikroskopie und FACS Messungen konnten wir die Expression von CXCR4 
und CXCR7 auf Thrombozyten zeigen. Die Oberflächenexpression von CXCR4 und 
CXCR7 in den beiden Patientenkollektiven wurde mittels FACS Messungen ermittelt. 
Die LV-Funktion wurde bei Studieneinschluss mittels Lävokardiographie während der 
Herzkatheteruntersuchung evaluiert. Danach erfolgten echokardiographische 
Verlaufskontrollen im Rahmen des Krankenhausaufenthaltes sowie nach 3 Monaten. 
Die Studienergebnisse deuten an, dass thrombozytäres CXCR7 SDF-1 Effekte 
vermitteln- und zu einer Erholung der Myokardfunktion nach akutem Koronarsyndrom 
beitragen könnte. Jedoch muss das regenerative Potential der Thrombozyten sowie 
insbesondere der Einfluss von CXCR4 und CXCR7 auf Stammzellfunktion sowie 
Rekrutierung noch besser verstanden werden um schlussendlich neue therapeutische 
Strategien für Patienten mit ischämischer Herzerkrankung zu entwickeln. 
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